Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Apple | Mobile |
---|---|
Business Dev & Design Entertainment | Social Media Tech Web Video |
Develops therapeutic tools for cancer patients.
Year Established: | |
Funding: | 25 |
Address: | San Francisco, CA 94103 |
Telephone: | 2147483647 |
Mobile: | |
Fax: | 415-230-3950 |
Mail: | |
Company URL: | http://www.actbiotech.com |
ACT Biotech Inc., a privately held biotechnology company developing a portfolio of oral kinase inhibitors as anti-cancer drugs, today announced the acceptance of the Investigational New Drug (IND) application for ACTB1003 by the US Food and Drug Administration (FDA). The company has now assembled a complete preclinical package, including manufacturing and toxicology studies, allowing ACTB1003 to enter a clinical trial. Read the story (PDF, 16K) >
ACT Biotech Inc. today announced the treatment of the first patients in a Phase 2 clinical trial of Telatinib in combination with standard-of-care chemotherapy for the treatment of gastric cancer. The Phase 2 multi-center trial is being conducted in the U.S. and in Spain with Principal Investigators at the University of Texas MD Anderson Cancer Center in Houston, Texas and the Vall d'Hebron University Hospital in Barcelona, Spain. Read the story (PDF, 12K) >
(San Francisco Business Times) Bayer's cost-cutting medicine is helping cure an entrepreneurial itch for one of its longtime executives. Wolf Busse, a 28-year veteran of the German drugmaker, started ACT Biotech Inc. in late April to develop and market oral cancer drugs from more than 300 compounds licensed from Bayer HealthCare LLC. That includes a Phase II compound that could net a cancer drug as early as 2013. Read the story >
(BioSpace) NGN Capital announced today the formation of ACT Biotech Inc., a new company dedicated to developing and commercializing targeted oral cancer drugs. ACT Biotech has entered into a license agreement with Bayer HealthCare LLC for a portfolio of clinical and early stage oncology assets. In conjunction with the agreement, ACT has raised $12 million in the first tranche of a Series A financing led by NGN Capital, New York. The company has also now initiated the syndication process to raise a total of $20 million, expected to be completed in the second quarter of 2008. Read the story >
NGN Capital LLC,Undisclosed Firm
Wolf D. Busse CEO Ali Fattaey Chief Operating and Scientific Officer